Longlong Zhang

Prof. Longlong Zhang

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ZLZixin Li
Zixin Li
YKYankun Ke
Yankun Ke
RZRui Zhang
Rui Zhang
RZRuya Zhang
Ruya Zhang
LZLonglong Zhang
Longlong Zhang
Cancer poses a significant threat to human health and lifespan and remains a persistent focus of biomedical research. Cyclin-dependent kinases 12 and 13 (CDK12/13) serve as crucial regulators of transcript elongation, the DNA damage response (DDR), and the maintenance of genomic stability. The selective inhibition of these kinases is highly effective in cancer therapy. This study systematically reviews the current landscape of the development of CDK12/13 inhibitors and degraders, elucidating their roles in various tumor types, with a particular emphasis on the applications in breast cancer. The advancement of CDK12/13-targeted therapeutics represents a convergence of fields and produces proven clinical benefits in oncology, pharmacology, and related disciplines. Consequently, elucidating the therapeutic mechanisms of CDK12/13 inhibition has significant translational value for precision oncology. In addition, through bioinformatics techniques, we identified new candidate targets for CDK12/13, contributing to the enrichment of the regulatory network of CDK12/13.

29 October 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YZYu Zhu
Yu Zhu
ZZZhibi Zhang
Zhibi Zhang
XDXueqin Dai
Xueqin Dai
WLWenjing Liu
Wenjing Liu
JSJian Sun
Jian Sun
Ceshi ChenCeshi Chen
Ceshi Chen
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by the poorest prognosis, and poses a significant threat to women's health. In this study, we identified two novel prieurianin-type limonoids extracted from Munronia henryi, one of which, named DHL-11, exhibited antitumor activity against TNBC cells. DHL-11 suppressed cell proliferation and migration, induced G2/M cell cycle arrest and apoptosis, and effectively increased the accumulation of reactive oxygen species (ROS) and cellular DNA damage in TNBC cells. Mechanistically, we found that DHL-11 binds to the non-catalytic pocket of IMPDH2 and disrupts the interaction between IMPDH2 and FANCI, leading to the degradation of the IMPDH2 protein. The decrease of IMPDH2 protein reduced guanine synthesis, increased ROS levels, and induced DNA damage. DHL-11 significantly inhibited the growth of breast cancer patient-derived organoids with high IMPDH2 expression. Furthermore, DHL-11 inhibited the growth and metastasis of TNBC xenografts in vivo with favorable biosafety profiles. Our findings highlight the potential of DHL-11 as a novel IMPDH2 degrader for the treatment of IMPDH2-positive TNBC.

28 August 2024 in Genes
Verified
Journal Article
Open access
PDF file
ZLZhu Liang
Zhu Liang
LZLonglong Zhang
Longlong Zhang
JCJingmei Cha
Jingmei Cha
CLChaocui Li
Chaocui Li
BMBingyu Mao
Bingyu Mao
ZC4H2 encodes a C4H2-type zinc finger protein, mutations of which lead to a spectrum of diseases known as ZC4H2 associated rare disorders (ZARD). In addition to neurological phenotypes, the most typical symptoms of ZARD are multiple joint contractures of varying degrees, accompanied by abnormal development of muscles and bones, and osteoporosis in some cases. The pathogenic mechanisms of such bone related phenotypes, however, remain unclear. Here, we showed that ZC4H2 is expressed in the developing bones in mice. ZC4H2 knockout mice were neonatal-lethal and smaller in size, with reduced calcification of long bones. Upon induced loss of ZC4H2 postnatally, the femoral bones developed an osteoporosis-like phenotype, with reduced bone mineral density, bone-volume fraction, and trabecular bone number. Knockdown of ZC4H2 showed no clear effect on the expression of osteogenic differentiation genes in in vitro models using mesenchymal stem cells. Interestingly, ZC4H2 knockdown significantly enhanced osteoclast differentiation and bone resorption in induced bone marrow-derived macrophages. We further confirmed that the number of osteoclasts in the long bone of ZC4H2 knockout mice was increased, as well as the expression of the serum bone resorption/osteoporosis marker CTX-1. Our study unveils a new role of ZC4H2 in osteoclast differentiation and bone development, providing new clues on the pathology of ZARD.

30 April 2026 in Bioorganic Chemistry
Verified
Journal Article
Closed access
YYYing Yan
Ying Yan
YWYane Wang
Yane Wang
XZXiong Zhang
Xiong Zhang
JAJunli Ao
Junli Ao
ZZZhibi Zhang
Zhibi Zhang
LTLei Tang
Lei Tang

19 March 2026 in Cells
Verified
Journal Article
Open access
PDF file
YKYankun Ke
Yankun Ke
ZLZixin Li
Zixin Li
HWHuaiyu Wang
Huaiyu Wang
YZYixuan Zhang
Yixuan Zhang
SXShiyu Xu
Shiyu Xu
LZLonglong Zhang
Longlong Zhang
Dogs represent a promising animal model for analyzing human neurodegenerative diseases, owing to their similarities to humans in nervous system architecture and behavioral phenotypes. Neural stem cells (NSCs) serve as a highly valuable in vitro experimental model for investigating neurogenesis, neurodegenerative disease pathogenesis, and neural molecular biology; however, studies on immortalized canine neural stem cell lines remain scarce. Herein, we successfully established an immortalized canine hippocampal neural stem cell line that can be continuously passaged in vitro via SV40 large T antigen (SV40LT) viral infection and subsequent cellular transformation. Both the immortalized NSCs and their normal parental counterparts differentiated into neuronal and glial lineages under induced differentiation conditions. Normal canine hippocampal NSCs can be passaged for no more than 10 generations, whereas the immortalized line can be passaged indefinitely while maintaining a normal karyotype. This immortalized canine hippocampal NSC line can act as a critical experimental tool for future research into neural differentiation mechanisms and stem cell-derived therapeutic strategies for neurological disorders in dogs.